843643-03-8

Basic information

• Product Name: 2-(6-aminopyridin-3-yl)propan-2-ol
• Synonyms: 2-(6-aminopyridin-3-yl)propan-2-ol;2-(6-Amino-3-pyridyl)propan-2-ol;2-Amino-5-(1-hydroxy-1-methylethyl)pyridine;6-Amino-alpha,alpha-dimethyl-3-pyridinemethanol;2-(6-Amino-pyridin-3-yl)-propan-2-ol（WS202218）
• CAS NO: 843643-03-8
• Molecular Formula: C₈H₁₂N₂O
• Molecular Weight: 152.19368
• Mol File: 843643-03-8.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(6-aminopyridin-3-yl)propan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(6-aminopyridin-3-yl)propan-2-ol(843643-03-8)
• EPA Substance Registry System: 2-(6-aminopyridin-3-yl)propan-2-ol(843643-03-8)

Safety Data

• Hazardous Substances Data: 843643-03-8(Hazardous Substances Data)

Usage

General Description

2-(6-aminopyridin-3-yl)propan-2-ol is a chemical compound with the molecular formula C8H12N2O. It is an organic compound that contains an amine and alcohol functional group. 2-(6-aminopyridin-3-yl)propan-2-ol is commonly used in the synthesis of pharmaceuticals and as an intermediate in organic synthesis. It is also known for its potential use as an anti-cancer agent due to its ability to inhibit the growth of cancer cells. Additionally, it has been studied for its potential use as a therapeutic agent for neurodegenerative diseases. 2-(6-aminopyridin-3-yl)propan-2-ol has a range of potential applications in the fields of medicine, pharmaceuticals, and organic chemistry.

Upstream product

• 36052-24-1 methyl 6-aminonicotinoate 
• 917-54-4 methyllithium 
• 53939-30-3 5-bromo-2-chloropyridine 
• 68700-91-4 2-chloro-5-(1-hydroxy-1-methylethyl)pyridine 
• 676-58-4 methylmagnesium chloride 

Downstream Products

• 1000845-17-9 [6-(1-hydroxy-1-methylethyl)imidazo[1,2-a]pyridin-2-yl](phenyl)methanone hydrobromide 
• 1000843-73-1 6-(1-hydroxy-1-methylethyl)-N-phenylimidazo[1,2-a]pyridine-2-carboxamide 

Relevant articles and documents

TYK2 INHIBITORS AND USES THEREOF

Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

New tetrahydropyrido pyrimidinecarboxylic compound or salt thereof

To provide a compound having an inhibitory activity for an androgen receptor. A tetrahydropyridopyrimidine compound represented by the following general formula (I) or a pharmaceutically acceptable thereof (in the formula, X and R are as defined in the specification).

Inhibitors of Bruton's Tyrosine Kinase

This application discloses 5-phenyl-1H-pyridin-2-one, 6-phenyl-2H-pyridazin-3-one, and 5-Phenyl-1H-pyrazin-2-one derivatives according to generic Formulae I-III: wherein, variables Q, R, X, X′, Y1, Y2, Y2′, Y3, Y4, Y5, m, and n are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-III and at least one carrier, diluent or excipient.